CT-388 activates both GLP-1 and GIP receptors with a unique signaling profile: Signal-biased dual agonism: Potent cAMP signaling at both GLP-1R and GIPR Minimal to no beta-arrestin recruitment at either receptor Reduced receptor internalization and desensitization Potentially prolonged pharmacological activity GLP-1 receptor activation: Appetite suppression via hypothalamic and brainstem receptors Glucose-dependent insulin secretion Glucagon suppression Gastric emptying delay GIP receptor activation: Additional insulin sensitization Enhanced lipid metabolism Complementary appetite regulation Potential adipose tissue remodeling benefits The biased signaling mechanism is the key differentiator
Side effects are rare, but some people may experience: Mild nausea or dizziness
Patients should check blood glucose levels more frequently than usual, and healthcare providers should consider reassessing hemoglobin A1c within 3 months
The landscape on compounded peptides has been moving fast
l-carnitine supplementation increases D-loop methylation in platelets, but this cannot be directly correlated to the TMAO increase observed in the same group
And it is related to cholesterol metabolism genes such as LXR, ATP-binding cassette transporter A1 (ABCA1), ATP-binding cassette G1 (ABCG1), acyl-coenzyme A oxidase 1 (ACOX1), apolipoprotein AI (apo AI) (Fig